A phase II study of docetaxel in combination with ZD 1839 (Iressa) [gefitinib] in previously treated patients with metastatic pancreatic cancer
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Docetaxel (Primary) ; Gefitinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 08 Nov 2009 Actual end date (1 Mar 2009) added as reported by ClinicalTrials.gov.
- 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2007 The expected completion date for this trial is now 1 Jun 2009.